The resurgence of infectious diseases on the African continent plays a major role in the increase in cancer occurrence. Whereas in developed countries the causes of occurrence of cancers are related mainly to non-infectious factors; cancers of infectious origin become a dramatic particularity in Africa. The proportion of virus-induced cancers may reach up to 75% of cancer cases in certain countries. Oncogenic viruses such as human papilloma virus (HPV), hepatitis viruses B and C, human herpes virus 8 and Epstein Barr virus in association with human immunodeficiency virus are the main viral etiologies of cancers in Africa, representing around 30% of cancers causes. Optimistically, 30% of cancers could be prevented in Africa. However, health burden prevails on the continent due to the weakness of health policy especially regarding preventive medicine, but also the limited technical facilities, poor manpower and insufficient political commitment. We felt urgent to review the state of the art of the question, and necessary to analyze and publicize the current epidemiological advances in oncogenic viruses and virus-induced cancers in Africa. Prevention implies understanding, which is compulsory to reverse the current trends and to potentially instate a control of virus-induced cancers.
References
[1]
Garcia, M., Jemal, A., Ward, E.M., Center, M.M., Hao, Y., Siegel, R.L. and Thun, M.J. (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta.
[2]
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, Lyon.
http://globocan.iarc.fr
[3]
Bray, F., Jemal, A., Grey, N., Ferlay, J. and Forman, D. (2012) Global Cancer Transitions According to the Human Development Index (2008-2030): A Population-Based Study. The Lancet Oncology, 13, 790-801. http://Thelancet.com/search/results
https://doi.org/10.1016/S1470-2045(12)70211-5
[4]
Lopez, A.D., Mathers, C.O., Ezzati, M., et al. (2006) Global and Regional Burden of Disease and Risk Factors, 2001: Systematic Analysis of Population Health Data. Lancet, 367, 1747-1757. https://doi.org/10.1016/S0140-6736(06)68770-9
[5]
De Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D. and Plummer, M. (2012) Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis. Lancet Oncology, 13, 607-615
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70176-6/fulltext
https://doi.org/10.1016/S1470-2045(12)70137-7
[6]
Bouvard, V., Baan, R., Straif, K., et al. (2009) On Behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Special Report: Policy. A Review of Human Carcinogens-Part B: Biological Agents. Lancet Oncology, 10, 321-322. https://doi.org/10.1016/S1470-2045(09)70096-8
[7]
Ly, A. (2011) Progression des cancers en Afrique: caractéristiques, altérité, nouvelles approches de santé publique. [Cancer Progression in Africa: Characteristics, Otherness, New Approaches to Public Health.] In: Kerouedan, D., Ed., Santé internationale. Les enjeux de santé au Sud, Sciences Po Presses, Paris, 121-140.
[8]
Ly, A. (2011) Enjeux et perspectives de la prévention des cancers dans les pays en développement. [Current Issues and Future Prospects in Cancer Prevention in Developing Countries.] Journal Africain du Cancer, 3, 268-272.
https://doi.org/10.1007/s12558-011-0178-5
[9]
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. https://doi.org/10.1002/ijc.25516
[10]
Ly, A. (2008) Cancer en Afrique: défis et perspectives. [Cancer in Africa: Challenges and Prospects.] ReMeD, 38, 1-24.
[11]
Ly, M., Ly, A., Rodrigues, M., Loriot, Y., Deberne, M., Boudou-Rouquette, P., Bathily, T. and Diallo, D. (2010) Le cancer en Afrique, un nouveau défi sanitaire. Exemples du Mali et de l’association OncoMali. [Cancer in Africa, a New Health Challenge. Examples from Mali and the OncoMali Association.] Bulletin du Cancer, 97, 965-968.
[12]
Guerin, S. and Hill, C. (2010) L’épidémiologie des cancers en France en 2010: Comparaison avec les états-Unis. [The Epidemiology of Cancers in France in 2010: A Comparison with the United States.] Bulletin du Cancer, 97, 47-54.
[13]
Dangou, J.M., Sambo, B.H., Moeti, M., Diarra Nama, A.J. (2009) Prévention et lutte contre le cancer dans la région Afrique de L’OMS: un appel à l’action. [Cancer Prevention and Control in the African Region: A Call to Action.] Journal Africain du Cancer, 1, 56-60. https://doi.org/10.1007/s12558-008-0008-6
[14]
Maréchal, V. and Piolot, T. (1999) Oncogenesis and Biological Cycles of Viruses. Virologie, 3, 297-308.
[15]
Newton, R., Beral, V. and Weiss, R.A., Eds. (1999) Cancer Surveys. Infections and Human Cancer. Imperial Cancer Research Fund, 33, 396.
[16]
Antoine Gessain, et al. (2000) Notion de causalité virus-cancer chez l’homme Med. [Concept of Virus-Cancer Causality in Humans.] Thérap, 6, 826-836.
[17]
Secondy, M. (2008) Classification des papillomavirus (HPV). [Classification of Human Papillomavirus (HPV).] Revue Francophone des Laboratoires, 405, 23-25.
https://doi.org/10.1016/S1773-035X(08)74274-6
[18]
Muñoz, N., Castellsague, X., de Gonzalez, A.B. and Gissmann, L. (2006) Chapter 1: HPV in the Etiology of Human Cancer. Vaccine, 24, S1-S10.
https://doi.org/10.1016/j.vaccine.2006.05.115
[19]
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.
https://doi.org/10.3322/caac.20107
[20]
Yugawa, T. and Kiyono, T. (2009) Molecular Mechanisms of Cervical Carcinogenesis by High-Risk Human Papillomaviruses: Novel Functions of E6 and E7 Oncoproteins. Reviews in Medical Virology, 19, 97-113.
https://doi.org/10.1002/rmv.605
[21]
Perz, J.F., Armstrong, G.L., Farrington, L.A., et al. (2006) The Contributions of Hepatitis B Virus and Hepatitis C Virus Infections to Cirrhosis and Primary Liver Cancer Worldwide. Journal of Hepatology, 45, 529-538.
https://doi.org/10.1016/j.jhep.2006.05.013
[22]
René Lambert (2009) Dossier Thématique: Cancer Du Foie Et Des Voies Biliaires (I.A.R.C) épidémiologie du carcinome hépatocellulaire (CHC) dans le monde Cancéro dig. [Thematic File: Cancer of the Liver and Bile Ducts: Epidemiology of Hepatocellular Carcinoma (HCC) in the World.] Vol. 1, 86-90.
[23]
Raza, S.A., Clifford, G.M. and Franceschi, S. (2007) Worldwide Variation in the Relative Importance of Hepatitis B and Hepatitis C Viruses in Hepatocellular Carcinoma: A Systematic Review. British Journal of Cancer, 96, 1127-1134.
https://doi.org/10.1038/sj.bjc.6603649
[24]
Germi, R., Baccard, M., Seigneurin, J.M. and Morand, P. (2011) Infections à virus Epstein-Barr. [Epstein-Barr Virus Infections.] EMC (Elsevier Masson, Paris), Infectious Diseases, 8-070-k-10.
[25]
Ferry Judith, A. (2006) Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. The Oncologist, 11, 375-383.
https://doi.org/10.1634/theoncologist.11-4-375
[26]
Raphaël, M. and Poirel, H.A. (2001) Virus Epstein-Barr et proliférations lymphoïdes B. [Epstein-Barr Virus and Lymphoid Proliferations B.] Revue Française des Laboratoires, 337, 59-63.
[27]
McLaughlin-Drubin, M.E. and Munger, K. (2007) Viruses Associated with Human Cancer. Biochimica et Biophysica Acta, 1782, 127-150.
https://doi.org/10.1016/j.bbadis.2007.12.005
[28]
Boulanger, E. and Gessain, A. (2006) Herpèsvirus humain 8: Bases moléculaires de l’oncogenèse et de la modulation de la réponse immunitaire. [Human Herpesvirus 8: Molecular Basis of Oncogenesis and Modulation of the Immune Response.] Virologie, 10, 369-382.
[29]
Morand, J.J., Lightburn, E., Simon, F. and Potte, J.H. (2007) Actualités sur la Maladie de Kaposi. [News about Kaposi’s Disease.] Medecine Tropicale, 67, 123-130.
[30]
Serraino, D., De Paoli, A., Zucchetto, A., Pennazza, S., Bruzzone, S., Spina, M., De Paoli, P., Rezza, G., Dal Maso, L. and Suligoi, B. (2010) The Impact of Kaposi Sarcoma and Non-Hodgkin Lymphoma on Mortality of People with AIDS in the Highly Active Antiretroviral Therapies Era. Cancer Epidemiology, 34, 257-261.
https://doi.org/10.1016/j.canep.2010.03.011
[31]
Gessain, A. (2005) Virus et lymphomes chez l’homme. Aspects épidémiologiques. [Viruses and Lymphomas in Humans: Epidemiological Aspects.] Revue Française des Laboratoires, 369, 36-40.
[32]
Proietti, F.A., Carneiro-Proietti, A.B., Catalan-Soares, B.C. and Murphy, E.L. (2005) Global Epidemiology of HTLV-I Infection and Associated Diseases. Oncogene, 24, 6058-6068. https://doi.org/10.1038/sj.onc.1208968
[33]
Gessain, A. (2011) Le rétrovirus humain oncogène HTLV-1: Epidémiologie descriptive et moléculaire, origine, évolution et aspects diagnostiques et maladies associées. [HTLV-1 Oncogenic Human Retrovirus: Descriptive and Molecular Epidemiology, Origin, Evolution, and Diagnostic Aspects and Associated Diseases.] Bulletin De La Societe De Pathologie Exotique, 104, 167-180.
https://doi.org/10.1007/s13149-011-0174-4
[34]
Matsuoka, M. and Jeang, K.T. (2007) Human T-Cell Leukaemia Virus Type 1 (HTLV-1) Infectivity and Cellular Transformation. Nature Reviews Cancer, 7, 270-280. https://doi.org/10.1038/nrc2111
[35]
Barbeau, B. and Mesnard, J.M. (2007) Does the HBZ Gene Represent a New Potential Target for the Treatment of Adult T-Cell Leukemia? International Reviews of Immunology, 26, 283-304. https://doi.org/10.1080/08830180701690843
[36]
Gessian, A., Yanagihara, R., Franchini, G., Garruto, R.M., Jenkins, C.L., Ajdukiewicz, A.B., Gallo, R.C. and Gajdusek, D.C. (1991) Highly Divergent Molecularvariants of Human T-Lymphotropic Virus Type I from Isolated Populations in Papua New Guinea and the Solomon Islands. Proceedings of the National Academy of Sciences, 88, 7694-7698.
https://doi.org/10.1073/pnas.88.17.7694
[37]
Plantier, J.C., Leoz, M., Dickerson, J.E., De Oliveira, F., Cordonnier, F., Lemee, V., Damond, F., Robertson, D.L. and Simon, F. (2009) A New Human Immunodeficiency Virus Derived from Gorillas. Nature Medicine, 15, 871-872.
https://doi.org/10.1038/nm.2016
[38]
Taylor, B.S. and Hammer, S.M. (2008) The Challenge of HIV-1 Subtype Diversity. The New England Journal of Medicine, 359, 1965-1966.
https://doi.org/10.1056/NEJMc086373
[39]
Sasco, A.J., Jaquet, A., Boidin, E., Ekouevi, D.K., Thouillot, F., Lemabec, T., Forstin, M.A., Renaudier, P., N’dom, P., Malvy, D. and Dabis, F. (2010) The Challenge of AIDS-Related Malignancies in Sub-Saharan Africa. PLoS ONE, 5, e8621.
https://doi.org/10.1371/journal.pone.0008621
[40]
ONUSIDA (2008) Le rapport sur l’épidémie mondiale de SIDA. [The Report on the Global AIDS Epidemic.] http://www.unaids.org/fr/dataanalysis/knowyourepidemic/
[41]
Shiels, M.S., Pfeiffer, R.M., Gail, M.H., Hall, H.I., Li, J., Chaturvedi, A.K., Bhatia, K., Uldrick, T.S., Yarchoan, R., Goedert, J.J. and Engels, E.A. (2011) Cancer Burden in the HIV-Affected Population in the United States. JNCI: Journal of the National Cancer Institute, 103, 753-762. https://doi.org/10.1093/jnci/djr076
[42]
Casper, C. (2011) The Increasing Burden of HIV-Associated Malignancies in Resource-Limited Regions. Annual Review of Medicine, 62, 157-170.
https://doi.org/10.1146/annurev-med-050409-103711
